Global Women Health Diagnostics Market Research and Analysis 2015-2022
Market Insights
The Women Health Diagnostics market is projected to witness a steady growth rate of around 8% during the forecasted period 2016-2022. Rising prevalence of infectious diseases in women coupled with the increasing incidences of the chronic & lifestyle disorders are the key factors driving the global women health diagnostics market. The rise in prevalence of infectious diseases such as HIV in women across the globe has influenced the growth of health diagnostics market in women. According to World Health Organization, around 17.4 million women aged 15 and above were living with HIV in 2014 and this number increased to 17.8 million in 2015. Adolescent girls and young girls aged 15-24 are specifically affected by HIV worldwide. In 2015, around 2.3 million adolescent girls and young women were living with HIV which constitutes around 60% of all the young individuals living with HIV. Furthermore, increasing incidences of chronic disorders such as breast cancer have utmost impacted the rising need for health diagnostics in women. Breast Cancer is one of the most common cancer types among women at global level. Along with it, it is also the primary cause of death from cancer among women worldwide. As per Breast Cancer Research Foundation, breast cancer represents 1 in 4 of all cancers in women. Around 1 in 8 women in the U.S. is expected to develop invasive breast cancer during the course of her lifetime. And approx. 252,710 new cases of invasive breast cancer are projected to be diagnosed in women in United States in the year 2017. Such fact widens the scope for the growth of global women health diagnostics market. Apart from it, supportive government initiatives by government & health organizations and rising awareness about fertility tests have also played a vital role in the growth of the global market. However, lack of skilled laboratory personnel and high cost of procedures & diagnostic imaging systems are the key factors restraining the growth of this market.
Geographical Insights
The global Women Health Diagnostics market can be segregated geographically into Europe, North America, North America and RoW. In 2016, North America held the dominating position in the global women health diagnostics market. The growth of the regional market is backed by the increasing incidences of lifestyle related disorders and rising prevalence of cancer among women within the region. According to BREASTCANCER.ORG, around 40,610 women in the U.S. are projected to die in 2017 from breast cancer. In the U.S., breast cancer death rates in women are higher than those for any other cancer besides lung cancer. Along with it, as per American Cancer Society around 14,240 women have died due to ovarian cancer in the U.S. in 2016. Such fact specifies the high prevalence of cancer within the region which positively influences the demand for women health diagnostic products. Apart from it, rising demand for fertility testing monitors and growing focus of women health diagnostic product manufacturers on expanding their presence within the regional boundaries are also playing a vital role in the growth of the region. Furthermore, Asia Pacific is the fastest growing region in the women health diagnostics market owing to the rising awareness among women related to several health disorders and increasing per capita income. Rising focus of international device manufacturers on strengthening their distribution networks within this region, epidemiological shift from the infectious diseases to chronic diseases within the regional boundaries and growing population within countries such as India and China are further boosting the growth of the women health diagnostics market in Asia Pacific.
The report includes detailed market overview, market determinants, company profiling, sector analysis, market segmentation, geographical analysis, patent analysis, strategic recommendations, key company analysis, gap analysis, key findings, market estimations, market insights, analyst insights and predictive analysis of the market.
Global Women Health Diagnostics market by region 2016
Source: OMR Analysis
Competitive Insights
The key players of Women Health Diagnostics market include Quest Diagnostics Inc., Abbott Laboratories, Becton, Dickinson and Company, F. Hoffmann-La Roche AG, GE Healthcare, Biomérieux SA and Koninklijke Philips N.V. Mergers and acquisitions, product launches, partnerships & collaborations and geographical expansion are some of the key strategies adopted by the market players to strengthen their KEY STRATEGY in the global market. On January 2017, Abbott Laboratories acquired St. Jude Medical Inc. (manufacturer of medical devices). The acquisition was valued around $25 billion. This strategic move is projected to strengthen Abbott’s leadership in global medical device market while offering products which in turn is projected to enhance its KEY STRATEGY in the women health diagnostic market.
Market Segmentation
The Women Health Diagnostics market is projected to witness a steady growth rate of around 8% during the forecasted period 2016-2022. Rising prevalence of infectious diseases in women coupled with the increasing incidences of the chronic & lifestyle disorders are the key factors driving the global women health diagnostics market. The rise in prevalence of infectious diseases such as HIV in women across the globe has influenced the growth of health diagnostics market in women. According to World Health Organization, around 17.4 million women aged 15 and above were living with HIV in 2014 and this number increased to 17.8 million in 2015. Adolescent girls and young girls aged 15-24 are specifically affected by HIV worldwide. In 2015, around 2.3 million adolescent girls and young women were living with HIV which constitutes around 60% of all the young individuals living with HIV. Furthermore, increasing incidences of chronic disorders such as breast cancer have utmost impacted the rising need for health diagnostics in women. Breast Cancer is one of the most common cancer types among women at global level. Along with it, it is also the primary cause of death from cancer among women worldwide. As per Breast Cancer Research Foundation, breast cancer represents 1 in 4 of all cancers in women. Around 1 in 8 women in the U.S. is expected to develop invasive breast cancer during the course of her lifetime. And approx. 252,710 new cases of invasive breast cancer are projected to be diagnosed in women in United States in the year 2017. Such fact widens the scope for the growth of global women health diagnostics market. Apart from it, supportive government initiatives by government & health organizations and rising awareness about fertility tests have also played a vital role in the growth of the global market. However, lack of skilled laboratory personnel and high cost of procedures & diagnostic imaging systems are the key factors restraining the growth of this market.
Geographical Insights
The global Women Health Diagnostics market can be segregated geographically into Europe, North America, North America and RoW. In 2016, North America held the dominating position in the global women health diagnostics market. The growth of the regional market is backed by the increasing incidences of lifestyle related disorders and rising prevalence of cancer among women within the region. According to BREASTCANCER.ORG, around 40,610 women in the U.S. are projected to die in 2017 from breast cancer. In the U.S., breast cancer death rates in women are higher than those for any other cancer besides lung cancer. Along with it, as per American Cancer Society around 14,240 women have died due to ovarian cancer in the U.S. in 2016. Such fact specifies the high prevalence of cancer within the region which positively influences the demand for women health diagnostic products. Apart from it, rising demand for fertility testing monitors and growing focus of women health diagnostic product manufacturers on expanding their presence within the regional boundaries are also playing a vital role in the growth of the region. Furthermore, Asia Pacific is the fastest growing region in the women health diagnostics market owing to the rising awareness among women related to several health disorders and increasing per capita income. Rising focus of international device manufacturers on strengthening their distribution networks within this region, epidemiological shift from the infectious diseases to chronic diseases within the regional boundaries and growing population within countries such as India and China are further boosting the growth of the women health diagnostics market in Asia Pacific.
The report includes detailed market overview, market determinants, company profiling, sector analysis, market segmentation, geographical analysis, patent analysis, strategic recommendations, key company analysis, gap analysis, key findings, market estimations, market insights, analyst insights and predictive analysis of the market.
Global Women Health Diagnostics market by region 2016
Source: OMR Analysis
Competitive Insights
The key players of Women Health Diagnostics market include Quest Diagnostics Inc., Abbott Laboratories, Becton, Dickinson and Company, F. Hoffmann-La Roche AG, GE Healthcare, Biomérieux SA and Koninklijke Philips N.V. Mergers and acquisitions, product launches, partnerships & collaborations and geographical expansion are some of the key strategies adopted by the market players to strengthen their KEY STRATEGY in the global market. On January 2017, Abbott Laboratories acquired St. Jude Medical Inc. (manufacturer of medical devices). The acquisition was valued around $25 billion. This strategic move is projected to strengthen Abbott’s leadership in global medical device market while offering products which in turn is projected to enhance its KEY STRATEGY in the women health diagnostic market.
Market Segmentation
- WOMEN HEALTH DIAGNOSTICS MARKET BY APPLICATION
- BREAST CANCER TESTING
- BIOPSIES
- MAMMOGRAPHY
- BLOOD CHEMISTRIES AND BLOOD CELL COUNT TESTS
- BREAST CANCER TUMOR MARKER TESTS
- OTHER DIAGNOSTIC IMAGING TESTS
- CERVICAL CANCER TESTING
- HPV TESTING
- PAP SMEAR
- OSTEOPOROSIS TESTING
- IN VITRO BLOOD TESTS
- BONE DENSITOMETRY
- PREGNANCY & FERTILITY TESTING
- PREGNANCY TESTING & OVULATION PREDICTION KITS
- LAB-BASED TESTING
- FERTILITY MONITORS
- OVARIAN CANCER TESTING
- DIAGNOSTIC IMAGING TESTS
- OVARIAN CANCER TUMOR MARKER TESTS
- OTHER TESTS
- INFECTIOUS DISEASE TESTING
- URINARY TRACT INFECTION TESTING
- TUBERCULOSIS TESTING
- MRSA TESTING
- HEPATITIS TESTING
- OTHER INFECTIOUS DISEASE TESTING
- PRENATAL GENETIC SCREENING AND CARRIER TESTING
- DOWN SYNDROME AND EDWARDS SYNDROME
- CYSTIC FIBROSIS
- TORCH INFECTIONS
- OTHER DISEASES
- ULTRASOUND TESTS
- OB/GYN IMAGING
- BREAST IMAGING
- SEXUALLY TRANSMITTED DISEASE TESTING
- HIV TESTING
- CT/NG (CHLAMYDIA TRACHOMATIS/NEISSERIA GONORRHOEAE) TESTING
- OTHER SEXUALLY TRANSMITTED DISEASES
- WOMEN HEALTH DIAGNOSTICS MARKET BY END USER
- DIAGNOSTIC AND IMAGING CENTERS
- HOSPITALS AND CLINICS
- HOME CARE
- Comprehensive research methodology of global Women Health Diagnostics market
- In-depth analysis of macro and micro factors influencing the market guided by key recommendations.
- Analysis of regional regulations and other government policies impacting the global Women Health Diagnostics market
- Insights about market determinants which are stimulating the global Women Health Diagnostics market
- Detailed and extensive market segments with regional distribution of researched revenues
- Extensive profiles and recent developments of market players
1. REPORT SUMMARY
1.1. RESEARCH METHODS AND TOOLS
1.2. MARKET BREAKDOWN
1.2.1. BY SEGMENTS
1.2.2. BY GEOGRAPHY
2. MARKET OVERVIEW AND INSIGHTS
2.1. DEFINITION
2.2. ANALYST & CURRENT MARKET TRENDS
2.2.1. KEY FINDINGS
2.2.2. RECOMMENDATION
2.2.3. CONCLUSION
2.3. REGULATIONS
2.3.1. UNITED STATES
2.3.2. EUROPEAN UNION
2.3.3. CHINA
2.3.4. INDIA
2.3.5. REST OF THE WORLD
2.4. PATENT ANALYSIS
3. MARKET DETERMINANT
3.1. MOTIVATORS
3.1.1. INCREASING INCIDENCES OF LIFESTYLE RELATED AND CHRONIC DISORDERS IN WOMEN
3.1.2. RISE IN THE NUMBER OF IMAGING CENTRES AND PRIVATE DIAGNOSTIC
3.1.3. RISING PREVALENCE OF INFECTIOUS DISEASES
3.1.4. GROWING ADOPTION OF POINT OF CARE & RAPID DIAGNOSTIC TESTS
3.1.5. SUPPORTIVE GOVERNMENT INITIATIVES BY GOVERNMENT AND HEALTHCARE ORGANIZATIONS
3.1.6. RISING AWARENESS ABOUT FERTILITY TESTING IN WOMEN
3.1.7. PUBLIC-PRIVATE PARTNERSHIPS TO IMPROVE INFRASTRUCTURE OF DIAGNOSTIC IMAGING CENTERS
3.2. RESTRAINTS
3.2.1. SHORTAGE OF SKILLED LABORATORY PERSONNEL
3.2.2. HIGH COST OF PROCEDURES AND DIAGNOSTIC IMAGING SYSTEMS
3.2.3. STRICT REGULATORY GUIDELINES
3.3. OPPORTUNITIES
3.3.1. RISE IN REGULATORY APPROVALS FOR IMMUNOASSAY DIAGNOSTIC TECHNIQUES
3.3.2. ENHANCING HEALTHCARE INFRASTRUCTURE IN EMERGING ECONOMIES
3.3.3. INCREASING R&D IN HEALTH DIAGNOSTICS
4. MARKET SEGMENTATION
4.1. WOMEN HEALTH DIAGNOSTICS MARKET BY APPLICATION
4.1.1. BREAST CANCER TESTING
4.1.1.1. BIOPSIES
4.1.1.2. MAMMOGRAPHY
4.1.1.3. BLOOD CHEMISTRIES AND BLOOD CELL COUNT TESTS
4.1.1.4. BREAST CANCER TUMOR MARKER TESTS
4.1.1.5. OTHER DIAGNOSTIC IMAGING TESTS
4.1.2. CERVICAL CANCER TESTING
4.1.2.1. HPV TESTING
4.1.2.2. PAP SMEAR
4.1.3. OSTEOPOROSIS TESTING
4.1.3.1. IN VITRO BLOOD TESTS
4.1.3.2. BONE DENSITOMETRY
4.1.4. PREGNANCY & FERTILITY TESTING
4.1.4.1. PREGNANCY TESTING & OVULATION PREDICTION KITS
4.1.4.2. LAB-BASED TESTING
4.1.4.3. FERTILITY MONITORS
4.1.5. OVARIAN CANCER TESTING
4.1.5.1. DIAGNOSTIC IMAGING TESTS
4.1.5.2. OVARIAN CANCER TUMOR MARKER TESTS
4.1.5.3. OTHER TESTS
4.1.6. INFECTIOUS DISEASE TESTING
4.1.6.1. URINARY TRACT INFECTION TESTING
4.1.6.2. TUBERCULOSIS TESTING
4.1.6.3. MRSA TESTING
4.1.6.4. HEPATITIS TESTING
4.1.6.5. OTHER INFECTIOUS DISEASE TESTING
4.1.7. PRENATAL GENETIC SCREENING AND CARRIER TESTING
4.1.7.1. DOWN SYNDROME AND EDWARDS SYNDROME
4.1.7.2. CYSTIC FIBROSIS
4.1.7.3. TORCH INFECTIONS
4.1.7.4. OTHER DISEASES
4.1.8. ULTRASOUND TESTS
4.1.8.1. OB/GYN IMAGING
4.1.8.2. BREAST IMAGING
4.1.9. SEXUALLY TRANSMITTED DISEASE TESTING
4.1.9.1. HIV TESTING
4.1.9.2. CT/NG (CHLAMYDIA TRACHOMATIS/NEISSERIA GONORRHOEAE) TESTING
4.1.9.3. OTHER SEXUALLY TRANSMITTED DISEASES
4.2. WOMEN HEALTH DIAGNOSTICS MARKET BY END USER
4.2.1. DIAGNOSTIC AND IMAGING CENTERS
4.2.2. HOSPITALS AND CLINICS
4.2.3. HOME CARE
5. COMPETITIVE LANDSCAPE
5.1. KEY STRATEGY ANALYSIS
5.2. KEY COMPANY ANALYSIS
6. REGIONAL ANALYSIS
6.1. NORTH AMERICA
6.1.1. UNITED STATES
6.1.2. CANADA
6.1.3. REST OF NORTH AMERICA
6.2. EUROPE
6.2.1. UNITED KINGDOM
6.2.2. FRANCE
6.2.3. GERMANY
6.2.4. ITALY
6.2.5. SPAIN
6.2.6. REST OF EUROPE
6.3. ASIA PACIFIC
6.3.1. INDIA
6.3.2. CHINA
6.3.3. JAPAN
6.3.4. REST OF ASIA PACIFIC
6.4. REST OF THE WORLD
7. COMPANY PROFILES
7.1. ABBOTT LABORATORIES
7.1.1. INTRODUCTION
7.1.2. ABBOTT LABORATORIES PRODUCT PORTFOLIO
7.1.3. ABBOTT LABORATORIES RECENT ACTIVITIES
7.2. ALERE INC.
7.2.1. INTRODUCTION
7.2.2. ALERE INC. PRODUCT PORTFOLIO
7.2.3. ALERE INC. RECENT ACTIVITIES
7.3. BIOMÉRIEUX SA
7.3.1. INTRODUCTION
7.3.2. BIOMÉRIEUX SA PRODUCT PORTFOLIO
7.3.3. BIOMÉRIEUX SA RECENT ACTIVITIES
7.4. BECTON, DICKINSON AND COMPANY
7.4.1. INTRODUCTION
7.4.2. BECTON, DICKINSON AND COMPANY PRODUCT PORTFOLIO
7.4.3. BECTON, DICKINSON AND COMPANY RECENT ACTIVITIES
7.5. DIALAB GMBH
7.5.1. INTRODUCTION
7.5.2. DIALAB GMBH PRODUCT PORTFOLIO
7.5.3. DIALAB GMBH RECENT ACTIVITIES
7.6. F. HOFFMANN-LA ROCHE AG
7.6.1. INTRODUCTION
7.6.2. F. HOFFMANN-LA ROCHE AG PRODUCT PORTFOLIO
7.6.3. F. HOFFMANN-LA ROCHE AG RECENT ACTIVITIES
7.7. FUJIFILM MEDICAL SYSTEMS USA
7.7.1. INTRODUCTION
7.7.2. FUJIFILM MEDICAL SYSTEMS USA PRODUCT PORTFOLIO
7.7.3. FUJIFILM MEDICAL SYSTEMS USA RECENT ACTIVITIES
7.8. GE HEALTHCARE
7.8.1. INTRODUCTION
7.8.2. GE HEALTHCARE PRODUCT PORTFOLIO
7.8.3. GE HEALTHCARE RECENT ACTIVITIES
7.9. GENMARK DIAGNOSTICS
7.9.1. INTRODUCTION
7.9.2. GENMARK DIAGNOSTICS PRODUCT PORTFOLIO
7.9.3. GENMARK DIAGNOSTICS RECENT ACTIVITIES
7.10. HOLOGIC, INC.
7.10.1. INTRODUCTION
7.10.2. HOLOGIC, INC. PRODUCT PORTFOLIO
7.10.3. HOLOGIC, INC. RECENT ACTIVITIES
7.11. IMMCO DIAGNOSTICS
7.11.1. INTRODUCTION
7.11.2. IMMCO DIAGNOSTICS PRODUCT PORTFOLIO
7.11.3. IMMCO DIAGNOSTICS RECENT ACTIVITIES
7.12. KONINKLIJKE PHILIPS N.V.
7.12.1. INTRODUCTION
7.12.2. KONINKLIJKE PHILIPS N.V. PRODUCT PORTFOLIO
7.12.3. KONINKLIJKE PHILIPS N.V. RECENT ACTIVITIES
7.13. LUMINEX CORPORATION
7.13.1. INTRODUCTION
7.13.2. LUMINEX CORPORATION PRODUCT PORTFOLIO
7.13.3. LUMINEX CORPORATION RECENT ACTIVITIES
7.14. NOVA BIOMEDICAL
7.14.1. INTRODUCTION
7.14.2. NOVA BIOMEDICAL PRODUCT PORTFOLIO
7.14.3. NOVA BIOMEDICAL RECENT ACTIVITIES
7.15. PHILIPS HEALTHCARE
7.15.1. INTRODUCTION
7.15.2. PHILIPS HEALTHCARE PRODUCT PORTFOLIO
7.15.3. PHILIPS HEALTHCARE RECENT ACTIVITIES
7.16. PERKINELMER INC.
7.16.1. INTRODUCTION
7.16.2. PERKINELMER INC. PRODUCT PORTFOLIO
7.16.3. PERKINELMER INC. RECENT ACTIVITIES
7.17. QUEST DIAGNOSTICS INC.
7.17.1. INTRODUCTION
7.17.2. QUEST DIAGNOSTICS INC. PRODUCT PORTFOLIO
7.17.3. QUEST DIAGNOSTICS INC. RECENT ACTIVITIES
7.18. ROCHE DIAGNOSTICS
7.18.1. INTRODUCTION
7.18.2. ROCHE DIAGNOSTICS PRODUCT PORTFOLIO
7.18.3. ROCHE DIAGNOSTICS RECENT ACTIVITIES
7.19. SIEMENS AG
7.19.1. INTRODUCTION
7.19.2. SIEMENS AG PRODUCT PORTFOLIO
7.19.3. SIEMENS AG RECENT ACTIVITIES
7.20. SOMAGEN DIAGNOSTICS
7.20.1. INTRODUCTION
7.20.2. SOMAGEN DIAGNOSTICS PRODUCT PORTFOLIO
7.20.3. SOMAGEN DIAGNOSTICS RECENT ACTIVITIES
1.1. RESEARCH METHODS AND TOOLS
1.2. MARKET BREAKDOWN
1.2.1. BY SEGMENTS
1.2.2. BY GEOGRAPHY
2. MARKET OVERVIEW AND INSIGHTS
2.1. DEFINITION
2.2. ANALYST & CURRENT MARKET TRENDS
2.2.1. KEY FINDINGS
2.2.2. RECOMMENDATION
2.2.3. CONCLUSION
2.3. REGULATIONS
2.3.1. UNITED STATES
2.3.2. EUROPEAN UNION
2.3.3. CHINA
2.3.4. INDIA
2.3.5. REST OF THE WORLD
2.4. PATENT ANALYSIS
3. MARKET DETERMINANT
3.1. MOTIVATORS
3.1.1. INCREASING INCIDENCES OF LIFESTYLE RELATED AND CHRONIC DISORDERS IN WOMEN
3.1.2. RISE IN THE NUMBER OF IMAGING CENTRES AND PRIVATE DIAGNOSTIC
3.1.3. RISING PREVALENCE OF INFECTIOUS DISEASES
3.1.4. GROWING ADOPTION OF POINT OF CARE & RAPID DIAGNOSTIC TESTS
3.1.5. SUPPORTIVE GOVERNMENT INITIATIVES BY GOVERNMENT AND HEALTHCARE ORGANIZATIONS
3.1.6. RISING AWARENESS ABOUT FERTILITY TESTING IN WOMEN
3.1.7. PUBLIC-PRIVATE PARTNERSHIPS TO IMPROVE INFRASTRUCTURE OF DIAGNOSTIC IMAGING CENTERS
3.2. RESTRAINTS
3.2.1. SHORTAGE OF SKILLED LABORATORY PERSONNEL
3.2.2. HIGH COST OF PROCEDURES AND DIAGNOSTIC IMAGING SYSTEMS
3.2.3. STRICT REGULATORY GUIDELINES
3.3. OPPORTUNITIES
3.3.1. RISE IN REGULATORY APPROVALS FOR IMMUNOASSAY DIAGNOSTIC TECHNIQUES
3.3.2. ENHANCING HEALTHCARE INFRASTRUCTURE IN EMERGING ECONOMIES
3.3.3. INCREASING R&D IN HEALTH DIAGNOSTICS
4. MARKET SEGMENTATION
4.1. WOMEN HEALTH DIAGNOSTICS MARKET BY APPLICATION
4.1.1. BREAST CANCER TESTING
4.1.1.1. BIOPSIES
4.1.1.2. MAMMOGRAPHY
4.1.1.3. BLOOD CHEMISTRIES AND BLOOD CELL COUNT TESTS
4.1.1.4. BREAST CANCER TUMOR MARKER TESTS
4.1.1.5. OTHER DIAGNOSTIC IMAGING TESTS
4.1.2. CERVICAL CANCER TESTING
4.1.2.1. HPV TESTING
4.1.2.2. PAP SMEAR
4.1.3. OSTEOPOROSIS TESTING
4.1.3.1. IN VITRO BLOOD TESTS
4.1.3.2. BONE DENSITOMETRY
4.1.4. PREGNANCY & FERTILITY TESTING
4.1.4.1. PREGNANCY TESTING & OVULATION PREDICTION KITS
4.1.4.2. LAB-BASED TESTING
4.1.4.3. FERTILITY MONITORS
4.1.5. OVARIAN CANCER TESTING
4.1.5.1. DIAGNOSTIC IMAGING TESTS
4.1.5.2. OVARIAN CANCER TUMOR MARKER TESTS
4.1.5.3. OTHER TESTS
4.1.6. INFECTIOUS DISEASE TESTING
4.1.6.1. URINARY TRACT INFECTION TESTING
4.1.6.2. TUBERCULOSIS TESTING
4.1.6.3. MRSA TESTING
4.1.6.4. HEPATITIS TESTING
4.1.6.5. OTHER INFECTIOUS DISEASE TESTING
4.1.7. PRENATAL GENETIC SCREENING AND CARRIER TESTING
4.1.7.1. DOWN SYNDROME AND EDWARDS SYNDROME
4.1.7.2. CYSTIC FIBROSIS
4.1.7.3. TORCH INFECTIONS
4.1.7.4. OTHER DISEASES
4.1.8. ULTRASOUND TESTS
4.1.8.1. OB/GYN IMAGING
4.1.8.2. BREAST IMAGING
4.1.9. SEXUALLY TRANSMITTED DISEASE TESTING
4.1.9.1. HIV TESTING
4.1.9.2. CT/NG (CHLAMYDIA TRACHOMATIS/NEISSERIA GONORRHOEAE) TESTING
4.1.9.3. OTHER SEXUALLY TRANSMITTED DISEASES
4.2. WOMEN HEALTH DIAGNOSTICS MARKET BY END USER
4.2.1. DIAGNOSTIC AND IMAGING CENTERS
4.2.2. HOSPITALS AND CLINICS
4.2.3. HOME CARE
5. COMPETITIVE LANDSCAPE
5.1. KEY STRATEGY ANALYSIS
5.2. KEY COMPANY ANALYSIS
6. REGIONAL ANALYSIS
6.1. NORTH AMERICA
6.1.1. UNITED STATES
6.1.2. CANADA
6.1.3. REST OF NORTH AMERICA
6.2. EUROPE
6.2.1. UNITED KINGDOM
6.2.2. FRANCE
6.2.3. GERMANY
6.2.4. ITALY
6.2.5. SPAIN
6.2.6. REST OF EUROPE
6.3. ASIA PACIFIC
6.3.1. INDIA
6.3.2. CHINA
6.3.3. JAPAN
6.3.4. REST OF ASIA PACIFIC
6.4. REST OF THE WORLD
7. COMPANY PROFILES
7.1. ABBOTT LABORATORIES
7.1.1. INTRODUCTION
7.1.2. ABBOTT LABORATORIES PRODUCT PORTFOLIO
7.1.3. ABBOTT LABORATORIES RECENT ACTIVITIES
7.2. ALERE INC.
7.2.1. INTRODUCTION
7.2.2. ALERE INC. PRODUCT PORTFOLIO
7.2.3. ALERE INC. RECENT ACTIVITIES
7.3. BIOMÉRIEUX SA
7.3.1. INTRODUCTION
7.3.2. BIOMÉRIEUX SA PRODUCT PORTFOLIO
7.3.3. BIOMÉRIEUX SA RECENT ACTIVITIES
7.4. BECTON, DICKINSON AND COMPANY
7.4.1. INTRODUCTION
7.4.2. BECTON, DICKINSON AND COMPANY PRODUCT PORTFOLIO
7.4.3. BECTON, DICKINSON AND COMPANY RECENT ACTIVITIES
7.5. DIALAB GMBH
7.5.1. INTRODUCTION
7.5.2. DIALAB GMBH PRODUCT PORTFOLIO
7.5.3. DIALAB GMBH RECENT ACTIVITIES
7.6. F. HOFFMANN-LA ROCHE AG
7.6.1. INTRODUCTION
7.6.2. F. HOFFMANN-LA ROCHE AG PRODUCT PORTFOLIO
7.6.3. F. HOFFMANN-LA ROCHE AG RECENT ACTIVITIES
7.7. FUJIFILM MEDICAL SYSTEMS USA
7.7.1. INTRODUCTION
7.7.2. FUJIFILM MEDICAL SYSTEMS USA PRODUCT PORTFOLIO
7.7.3. FUJIFILM MEDICAL SYSTEMS USA RECENT ACTIVITIES
7.8. GE HEALTHCARE
7.8.1. INTRODUCTION
7.8.2. GE HEALTHCARE PRODUCT PORTFOLIO
7.8.3. GE HEALTHCARE RECENT ACTIVITIES
7.9. GENMARK DIAGNOSTICS
7.9.1. INTRODUCTION
7.9.2. GENMARK DIAGNOSTICS PRODUCT PORTFOLIO
7.9.3. GENMARK DIAGNOSTICS RECENT ACTIVITIES
7.10. HOLOGIC, INC.
7.10.1. INTRODUCTION
7.10.2. HOLOGIC, INC. PRODUCT PORTFOLIO
7.10.3. HOLOGIC, INC. RECENT ACTIVITIES
7.11. IMMCO DIAGNOSTICS
7.11.1. INTRODUCTION
7.11.2. IMMCO DIAGNOSTICS PRODUCT PORTFOLIO
7.11.3. IMMCO DIAGNOSTICS RECENT ACTIVITIES
7.12. KONINKLIJKE PHILIPS N.V.
7.12.1. INTRODUCTION
7.12.2. KONINKLIJKE PHILIPS N.V. PRODUCT PORTFOLIO
7.12.3. KONINKLIJKE PHILIPS N.V. RECENT ACTIVITIES
7.13. LUMINEX CORPORATION
7.13.1. INTRODUCTION
7.13.2. LUMINEX CORPORATION PRODUCT PORTFOLIO
7.13.3. LUMINEX CORPORATION RECENT ACTIVITIES
7.14. NOVA BIOMEDICAL
7.14.1. INTRODUCTION
7.14.2. NOVA BIOMEDICAL PRODUCT PORTFOLIO
7.14.3. NOVA BIOMEDICAL RECENT ACTIVITIES
7.15. PHILIPS HEALTHCARE
7.15.1. INTRODUCTION
7.15.2. PHILIPS HEALTHCARE PRODUCT PORTFOLIO
7.15.3. PHILIPS HEALTHCARE RECENT ACTIVITIES
7.16. PERKINELMER INC.
7.16.1. INTRODUCTION
7.16.2. PERKINELMER INC. PRODUCT PORTFOLIO
7.16.3. PERKINELMER INC. RECENT ACTIVITIES
7.17. QUEST DIAGNOSTICS INC.
7.17.1. INTRODUCTION
7.17.2. QUEST DIAGNOSTICS INC. PRODUCT PORTFOLIO
7.17.3. QUEST DIAGNOSTICS INC. RECENT ACTIVITIES
7.18. ROCHE DIAGNOSTICS
7.18.1. INTRODUCTION
7.18.2. ROCHE DIAGNOSTICS PRODUCT PORTFOLIO
7.18.3. ROCHE DIAGNOSTICS RECENT ACTIVITIES
7.19. SIEMENS AG
7.19.1. INTRODUCTION
7.19.2. SIEMENS AG PRODUCT PORTFOLIO
7.19.3. SIEMENS AG RECENT ACTIVITIES
7.20. SOMAGEN DIAGNOSTICS
7.20.1. INTRODUCTION
7.20.2. SOMAGEN DIAGNOSTICS PRODUCT PORTFOLIO
7.20.3. SOMAGEN DIAGNOSTICS RECENT ACTIVITIES
LIST OF TABLES
Table # 1 GLOBAL WOMEN HEALTH DIAGNOSTICS MARKET RESEARCH AND ANALYSIS, BY APPLICATION 2015-2022 ($ MILLION)
Table # 2 GLOBAL BREAST CANCER TESTING MARKET RESEARCH AND ANALYSIS 2015-2022 ($ MILLION)
Table # 3 GLOBAL BIOPSIES MARKET RESEARCH AND ANALYSIS 2015-2022 ($ MILLION)
Table # 4 GLOBAL MAMMOGRAPHY MARKET RESEARCH AND ANALYSIS 2015-2022 ($ MILLION)
Table # 5 GLOBAL BLOOD CHEMISTRIES AND BLOOD CELL COUNT TESTS MARKET RESEARCH AND ANALYSIS 2015-2022 ($ MILLION)
Table # 6 GLOBAL BLOOD CANCER TUMOR MARKER TESTS MARKET RESEARCH AND ANALYSIS 2015-2022 ($ MILLION)
Table # 7 GLOBAL OTHER DIAGNOSTIC IMAGING TESTS MARKET RESEARCH AND ANALYSIS 2015-2022 ($ MILLION)
Table # 8 GLOBAL CERVICAL CANCER TESTING MARKET RESEARCH AND ANALYSIS 2015-2022 ($ MILLION)
Table # 9 GLOBAL HPV TESTING MARKET RESEARCH AND ANALYSIS 2015-2022 ($ MILLION)
Table # 10 GLOBAL PAP SMEAR MARKET RESEARCH AND ANALYSIS 2015-2022 ($ MILLION)
Table # 11 GLOBAL OSTEOPOROSIS TESTING MARKET RESEARCH AND ANALYSIS 2015-2022 ($ MILLION)
Table # 12 GLOBAL IN VITRO BLOOD TESTS MARKET RESEARCH AND ANALYSIS 2015-2022 ($ MILLION)
Table # 13 GLOBAL BONE DENSITOMETRY TESTS MARKET RESEARCH AND ANALYSIS 2015-2022 ($ MILLION)
Table # 14 GLOBAL PREGNANCY & FERTILITY TESTING MARKET RESEARCH AND ANALYSIS 2015-2022 ($ MILLION)
Table # 15 GLOBAL PREGNANCY TESTING & OVULATION PREDICTION KITS MARKET RESEARCH AND ANALYSIS 2015-2022 ($ MILLION)
Table # 16 GLOBAL LAB-BASED TESTING MARKET RESEARCH AND ANALYSIS 2015-2022 ($ MILLION)
Table # 17 GLOBAL FERTILITY MONITORS MARKET RESEARCH AND ANALYSIS 2015-2022 ($ MILLION)
Table # 18 GLOBAL OVARIAN CANCER TESTING MARKET RESEARCH AND ANALYSIS 2015-2022 ($ MILLION)
Table # 19 GLOBAL DIAGNOSTIC IMAGING TESTS MARKET RESEARCH AND ANALYSIS 2015-2022 ($ MILLION)
Table # 20 GLOBAL OVARIAN CANCER TUMOR MARKER TESTS MARKET RESEARCH AND ANALYSIS 2015-2022 ($ MILLION)
Table # 21 GLOBAL OTHER TESTS MARKET RESEARCH AND ANALYSIS 2015-2022 ($ MILLION)
Table # 22 GLOBAL INFECTIOUS DISEASE TESTING MARKET RESEARCH AND ANALYSIS 2015-2022 ($ MILLION)
Table # 23 GLOBAL URINARY TRACT INFECTION TESTING MARKET RESEARCH AND ANALYSIS 2015-2022 ($ MILLION)
Table # 24 GLOBAL TUBERCULOSIS TESTING MARKET RESEARCH AND ANALYSIS 2015-2022 ($ MILLION)
Table # 25 GLOBAL MRSA TESTING MARKET RESEARCH AND ANALYSIS 2015-2022 ($ MILLION)
Table # 26 GLOBAL HEPATITIS TESTING MARKET RESEARCH AND ANALYSIS 2015-2022 ($ MILLION)
Table # 27 GLOBAL OTHER INFECTIOUS DISEASE TESTING MARKET RESEARCH AND ANALYSIS 2015-2022 ($ MILLION)
Table # 28 GLOBAL PRENATAL GENETIC SCREENING AND CARRIER TESTING MARKET RESEARCH AND ANALYSIS 2015-2022 ($ MILLION)
Table # 29 GLOBAL DOWN SYNDROME AND EDWARDS SYNDROME MARKET RESEARCH AND ANALYSIS 2015-2022 ($ MILLION)
Table # 30 GLOBAL CYSTIC FIBROSIS MARKET RESEARCH AND ANALYSIS 2015-2022 ($ MILLION)
Table # 31 GLOBAL TORCH INFECTIONS MARKET RESEARCH AND ANALYSIS 2015-2022 ($ MILLION)
Table # 32 GLOBAL OTHER DISEASES MARKET RESEARCH AND ANALYSIS 2015-2022 ($ MILLION)
Table # 33 GLOBAL ULTRASOUND TESTS MARKET RESEARCH AND ANALYSIS 2015-2022 ($ MILLION)
Table # 34 GLOBAL OB/GYN IMAGING MARKET RESEARCH AND ANALYSIS 2015-2022 ($ MILLION)
Table # 35 GLOBAL BREAST IMAGING MARKET RESEARCH AND ANALYSIS 2015-2022 ($ MILLION)
Table # 36 GLOBAL SEXUALLY TRANSMITTED DISEASE TESTING MARKET RESEARCH AND ANALYSIS 2015-2022 ($ MILLION)
Table # 37 GLOBAL HIV TESTING MARKET RESEARCH AND ANALYSIS 2015-2022 ($ MILLION)
Table # 38 GLOBAL CT/NG TESTING MARKET RESEARCH AND ANALYSIS 2015-2022 ($ MILLION)
Table # 39 GLOBAL OTHER SEXUALLY TRANSMITTED DISEASES MARKET RESEARCH AND ANALYSIS 2015-2022 ($ MILLION)
Table # 40 GLOBAL WOMEN HEALTH DIAGNOSTICS MARKET RESEARCH AND ANALYSIS, BY END USER 2015-2022 ($ MILLION)
Table # 41 GLOBAL DIAGNOSTIC AND IMAGING CENTERS MARKET RESEARCH AND ANALYSIS 2015-2022 ($ MILLION)
Table # 42 GLOBAL HOSPITALS AND CLINICS MARKET RESEARCH AND ANALYSIS, BY CONNECTOR 2015-2022 ($ MILLION)
Table # 43 GLOBAL HOME CARE MARKET RESEARCH AND ANALYSIS 2015-2022 ($ MILLION)
Table # 44 ABBOTT LABORATORIES PRODUCT PORTFOLIO
Table # 45 ABBOTT LABORATORIES RECENT ACTIVITIES
Table # 46 ALERE INC. PRODUCT PORTFOLIO
Table # 47 ALERE INC. RECENT ACTIVITIES
Table # 48 BIOMÉRIEUX SA PRODUCT PORTFOLIO
Table # 49 BIOMÉRIEUX SA RECENT ACTIVITIES
Table # 50 BECTON, DICKINSON AND COMPANY PRODUCT PORTFOLIO
Table # 51 BECTON, DICKINSON AND COMPANY RECENT ACTIVITIES
Table # 52 DIALAB GMBH PRODUCT PORTFOLIO
Table # 53 DIALAB GMBH RECENT ACTIVITIES
Table # 54 F. HOFFMANN-LA ROCHE AG PRODUCT PORTFOLIO
Table # 55 F. HOFFMANN-LA ROCHE AG RECENT ACTIVITIES
Table # 56 FUJIFILM MEDICAL SYSTEMS USA PRODUCT PORTFOLIO
Table # 57 FUJIFILM MEDICAL SYSTEMS USA RECENT ACTIVITIES
Table # 58 GE HEALTHCARE PRODUCT PORTFOLIO
Table # 59 GE HEALTHCARE RECENT ACTIVITIES
Table # 60 GENMARK DIAGNOSTICS PRODUCT PORTFOLIO
Table # 61 GENMARK DIAGNOSTICS RECENT ACTIVITIES
Table # 62 HOLOGIC, INC. PRODUCT PORTFOLIO
Table # 63 HOLOGIC, INC. RECENT ACTIVITIES
Table # 64 IMMCO DIAGNOSTICS PRODUCT PORTFOLIO
Table # 65 IMMCO DIAGNOSTICS RECENT ACTIVITIES
Table # 66 KONINKLIJKE PHILIPS N.V. PRODUCT PORTFOLIO
Table # 67 KONINKLIJKE PHILIPS N.V. RECENT ACTIVITIES
Table # 68 LUMINEX CORPORATION PRODUCT PORTFOLIO
Table # 69 LUMINEX CORPORATION RECENT ACTIVITIES
Table # 70 NOVA BIOMEDICAL PRODUCT PORTFOLIO
Table # 71 NOVA BIOMEDICAL RECENT ACTIVITIES
Table # 72 PHILIPS HEALTHCARE PRODUCT PORTFOLIO
Table # 73 PHILIPS HEALTHCARE RECENT ACTIVITIES
Table # 74 PERKINELMER INC. PRODUCT PORTFOLIO
Table # 75 PERKINELMER INC. RECENT ACTIVITIES
Table # 76 QUEST DIAGNOSTICS INC. PRODUCT PORTFOLIO
Table # 77 QUEST DIAGNOSTICS INC. RECENT ACTIVITIES
Table # 78 ROCHE DIAGNOSTICS PRODUCT PORTFOLIO
Table # 79 ROCHE DIAGNOSTICS RECENT ACTIVITIES
Table # 80 SIEMENS AG PRODUCT PORTFOLIO
Table # 81 SIEMENS AG RECENT ACTIVITIES
Table # 82 SOMAGEN DIAGNOSTICS PRODUCT PORTFOLIO
Table # 83 SOMAGEN DIAGNOSTICS RECENT ACTIVITIES
Table # 1 GLOBAL WOMEN HEALTH DIAGNOSTICS MARKET RESEARCH AND ANALYSIS, BY APPLICATION 2015-2022 ($ MILLION)
Table # 2 GLOBAL BREAST CANCER TESTING MARKET RESEARCH AND ANALYSIS 2015-2022 ($ MILLION)
Table # 3 GLOBAL BIOPSIES MARKET RESEARCH AND ANALYSIS 2015-2022 ($ MILLION)
Table # 4 GLOBAL MAMMOGRAPHY MARKET RESEARCH AND ANALYSIS 2015-2022 ($ MILLION)
Table # 5 GLOBAL BLOOD CHEMISTRIES AND BLOOD CELL COUNT TESTS MARKET RESEARCH AND ANALYSIS 2015-2022 ($ MILLION)
Table # 6 GLOBAL BLOOD CANCER TUMOR MARKER TESTS MARKET RESEARCH AND ANALYSIS 2015-2022 ($ MILLION)
Table # 7 GLOBAL OTHER DIAGNOSTIC IMAGING TESTS MARKET RESEARCH AND ANALYSIS 2015-2022 ($ MILLION)
Table # 8 GLOBAL CERVICAL CANCER TESTING MARKET RESEARCH AND ANALYSIS 2015-2022 ($ MILLION)
Table # 9 GLOBAL HPV TESTING MARKET RESEARCH AND ANALYSIS 2015-2022 ($ MILLION)
Table # 10 GLOBAL PAP SMEAR MARKET RESEARCH AND ANALYSIS 2015-2022 ($ MILLION)
Table # 11 GLOBAL OSTEOPOROSIS TESTING MARKET RESEARCH AND ANALYSIS 2015-2022 ($ MILLION)
Table # 12 GLOBAL IN VITRO BLOOD TESTS MARKET RESEARCH AND ANALYSIS 2015-2022 ($ MILLION)
Table # 13 GLOBAL BONE DENSITOMETRY TESTS MARKET RESEARCH AND ANALYSIS 2015-2022 ($ MILLION)
Table # 14 GLOBAL PREGNANCY & FERTILITY TESTING MARKET RESEARCH AND ANALYSIS 2015-2022 ($ MILLION)
Table # 15 GLOBAL PREGNANCY TESTING & OVULATION PREDICTION KITS MARKET RESEARCH AND ANALYSIS 2015-2022 ($ MILLION)
Table # 16 GLOBAL LAB-BASED TESTING MARKET RESEARCH AND ANALYSIS 2015-2022 ($ MILLION)
Table # 17 GLOBAL FERTILITY MONITORS MARKET RESEARCH AND ANALYSIS 2015-2022 ($ MILLION)
Table # 18 GLOBAL OVARIAN CANCER TESTING MARKET RESEARCH AND ANALYSIS 2015-2022 ($ MILLION)
Table # 19 GLOBAL DIAGNOSTIC IMAGING TESTS MARKET RESEARCH AND ANALYSIS 2015-2022 ($ MILLION)
Table # 20 GLOBAL OVARIAN CANCER TUMOR MARKER TESTS MARKET RESEARCH AND ANALYSIS 2015-2022 ($ MILLION)
Table # 21 GLOBAL OTHER TESTS MARKET RESEARCH AND ANALYSIS 2015-2022 ($ MILLION)
Table # 22 GLOBAL INFECTIOUS DISEASE TESTING MARKET RESEARCH AND ANALYSIS 2015-2022 ($ MILLION)
Table # 23 GLOBAL URINARY TRACT INFECTION TESTING MARKET RESEARCH AND ANALYSIS 2015-2022 ($ MILLION)
Table # 24 GLOBAL TUBERCULOSIS TESTING MARKET RESEARCH AND ANALYSIS 2015-2022 ($ MILLION)
Table # 25 GLOBAL MRSA TESTING MARKET RESEARCH AND ANALYSIS 2015-2022 ($ MILLION)
Table # 26 GLOBAL HEPATITIS TESTING MARKET RESEARCH AND ANALYSIS 2015-2022 ($ MILLION)
Table # 27 GLOBAL OTHER INFECTIOUS DISEASE TESTING MARKET RESEARCH AND ANALYSIS 2015-2022 ($ MILLION)
Table # 28 GLOBAL PRENATAL GENETIC SCREENING AND CARRIER TESTING MARKET RESEARCH AND ANALYSIS 2015-2022 ($ MILLION)
Table # 29 GLOBAL DOWN SYNDROME AND EDWARDS SYNDROME MARKET RESEARCH AND ANALYSIS 2015-2022 ($ MILLION)
Table # 30 GLOBAL CYSTIC FIBROSIS MARKET RESEARCH AND ANALYSIS 2015-2022 ($ MILLION)
Table # 31 GLOBAL TORCH INFECTIONS MARKET RESEARCH AND ANALYSIS 2015-2022 ($ MILLION)
Table # 32 GLOBAL OTHER DISEASES MARKET RESEARCH AND ANALYSIS 2015-2022 ($ MILLION)
Table # 33 GLOBAL ULTRASOUND TESTS MARKET RESEARCH AND ANALYSIS 2015-2022 ($ MILLION)
Table # 34 GLOBAL OB/GYN IMAGING MARKET RESEARCH AND ANALYSIS 2015-2022 ($ MILLION)
Table # 35 GLOBAL BREAST IMAGING MARKET RESEARCH AND ANALYSIS 2015-2022 ($ MILLION)
Table # 36 GLOBAL SEXUALLY TRANSMITTED DISEASE TESTING MARKET RESEARCH AND ANALYSIS 2015-2022 ($ MILLION)
Table # 37 GLOBAL HIV TESTING MARKET RESEARCH AND ANALYSIS 2015-2022 ($ MILLION)
Table # 38 GLOBAL CT/NG TESTING MARKET RESEARCH AND ANALYSIS 2015-2022 ($ MILLION)
Table # 39 GLOBAL OTHER SEXUALLY TRANSMITTED DISEASES MARKET RESEARCH AND ANALYSIS 2015-2022 ($ MILLION)
Table # 40 GLOBAL WOMEN HEALTH DIAGNOSTICS MARKET RESEARCH AND ANALYSIS, BY END USER 2015-2022 ($ MILLION)
Table # 41 GLOBAL DIAGNOSTIC AND IMAGING CENTERS MARKET RESEARCH AND ANALYSIS 2015-2022 ($ MILLION)
Table # 42 GLOBAL HOSPITALS AND CLINICS MARKET RESEARCH AND ANALYSIS, BY CONNECTOR 2015-2022 ($ MILLION)
Table # 43 GLOBAL HOME CARE MARKET RESEARCH AND ANALYSIS 2015-2022 ($ MILLION)
Table # 44 ABBOTT LABORATORIES PRODUCT PORTFOLIO
Table # 45 ABBOTT LABORATORIES RECENT ACTIVITIES
Table # 46 ALERE INC. PRODUCT PORTFOLIO
Table # 47 ALERE INC. RECENT ACTIVITIES
Table # 48 BIOMÉRIEUX SA PRODUCT PORTFOLIO
Table # 49 BIOMÉRIEUX SA RECENT ACTIVITIES
Table # 50 BECTON, DICKINSON AND COMPANY PRODUCT PORTFOLIO
Table # 51 BECTON, DICKINSON AND COMPANY RECENT ACTIVITIES
Table # 52 DIALAB GMBH PRODUCT PORTFOLIO
Table # 53 DIALAB GMBH RECENT ACTIVITIES
Table # 54 F. HOFFMANN-LA ROCHE AG PRODUCT PORTFOLIO
Table # 55 F. HOFFMANN-LA ROCHE AG RECENT ACTIVITIES
Table # 56 FUJIFILM MEDICAL SYSTEMS USA PRODUCT PORTFOLIO
Table # 57 FUJIFILM MEDICAL SYSTEMS USA RECENT ACTIVITIES
Table # 58 GE HEALTHCARE PRODUCT PORTFOLIO
Table # 59 GE HEALTHCARE RECENT ACTIVITIES
Table # 60 GENMARK DIAGNOSTICS PRODUCT PORTFOLIO
Table # 61 GENMARK DIAGNOSTICS RECENT ACTIVITIES
Table # 62 HOLOGIC, INC. PRODUCT PORTFOLIO
Table # 63 HOLOGIC, INC. RECENT ACTIVITIES
Table # 64 IMMCO DIAGNOSTICS PRODUCT PORTFOLIO
Table # 65 IMMCO DIAGNOSTICS RECENT ACTIVITIES
Table # 66 KONINKLIJKE PHILIPS N.V. PRODUCT PORTFOLIO
Table # 67 KONINKLIJKE PHILIPS N.V. RECENT ACTIVITIES
Table # 68 LUMINEX CORPORATION PRODUCT PORTFOLIO
Table # 69 LUMINEX CORPORATION RECENT ACTIVITIES
Table # 70 NOVA BIOMEDICAL PRODUCT PORTFOLIO
Table # 71 NOVA BIOMEDICAL RECENT ACTIVITIES
Table # 72 PHILIPS HEALTHCARE PRODUCT PORTFOLIO
Table # 73 PHILIPS HEALTHCARE RECENT ACTIVITIES
Table # 74 PERKINELMER INC. PRODUCT PORTFOLIO
Table # 75 PERKINELMER INC. RECENT ACTIVITIES
Table # 76 QUEST DIAGNOSTICS INC. PRODUCT PORTFOLIO
Table # 77 QUEST DIAGNOSTICS INC. RECENT ACTIVITIES
Table # 78 ROCHE DIAGNOSTICS PRODUCT PORTFOLIO
Table # 79 ROCHE DIAGNOSTICS RECENT ACTIVITIES
Table # 80 SIEMENS AG PRODUCT PORTFOLIO
Table # 81 SIEMENS AG RECENT ACTIVITIES
Table # 82 SOMAGEN DIAGNOSTICS PRODUCT PORTFOLIO
Table # 83 SOMAGEN DIAGNOSTICS RECENT ACTIVITIES
LIST OF FIGURES
Figure # 1 NORTH AMERICA MARKET RESEARCH AND ANALYSIS, 2015-2022
Figure # 2 US MARKET RESEARCH AND ANALYSIS, 2015-2022
Figure # 3 CANADA MARKET RESEARCH AND ANALYSIS, 2015-2022
Figure # 4 EUROPEAN MARKET RESEARCH AND ANALYSIS, 2015-2022
Figure # 5 UK MARKET RESEARCH AND ANALYSIS, 2015-2022
Figure # 6 FRANCE MARKET RESEARCH AND ANALYSIS, 2015-2022
Figure # 7 GERMANY MARKET RESEARCH AND ANALYSIS, 2015-2022
Figure # 8 ITALY MARKET RESEARCH AND ANALYSIS, 2015-2022
Figure # 9 SPAIN MARKET RESEARCH AND ANALYSIS, 2015-2022
Figure # 10 ROE MARKET RESEARCH AND ANALYSIS, 2015-2022
Figure # 11 ASIA PACIFIC MARKET RESEARCH AND ANALYSIS, 2015-2022
Figure # 12 INDIA MARKET RESEARCH AND ANALYSIS, 2015-2022
Figure # 13 CHINA MARKET RESEARCH AND ANALYSIS, 2015-2022
Figure # 14 JAPAN MARKET RESEARCH AND ANALYSIS, 2015-2022
Figure # 15 ROAPAC MARKET RESEARCH AND ANALYSIS, 2015-2022
Figure # 16 REST OF THE WORLD MARKET RESEARCH AND ANALYSIS, 2015-2022
Figure # 1 NORTH AMERICA MARKET RESEARCH AND ANALYSIS, 2015-2022
Figure # 2 US MARKET RESEARCH AND ANALYSIS, 2015-2022
Figure # 3 CANADA MARKET RESEARCH AND ANALYSIS, 2015-2022
Figure # 4 EUROPEAN MARKET RESEARCH AND ANALYSIS, 2015-2022
Figure # 5 UK MARKET RESEARCH AND ANALYSIS, 2015-2022
Figure # 6 FRANCE MARKET RESEARCH AND ANALYSIS, 2015-2022
Figure # 7 GERMANY MARKET RESEARCH AND ANALYSIS, 2015-2022
Figure # 8 ITALY MARKET RESEARCH AND ANALYSIS, 2015-2022
Figure # 9 SPAIN MARKET RESEARCH AND ANALYSIS, 2015-2022
Figure # 10 ROE MARKET RESEARCH AND ANALYSIS, 2015-2022
Figure # 11 ASIA PACIFIC MARKET RESEARCH AND ANALYSIS, 2015-2022
Figure # 12 INDIA MARKET RESEARCH AND ANALYSIS, 2015-2022
Figure # 13 CHINA MARKET RESEARCH AND ANALYSIS, 2015-2022
Figure # 14 JAPAN MARKET RESEARCH AND ANALYSIS, 2015-2022
Figure # 15 ROAPAC MARKET RESEARCH AND ANALYSIS, 2015-2022
Figure # 16 REST OF THE WORLD MARKET RESEARCH AND ANALYSIS, 2015-2022
